2006-1-15 8627 65799535 yest@cjsc.com.cn 8627 65799773 duanll@cjsc.com.cn 600276? 600557 600993 600488 000790 600976 002004 600161 A 600849 600812 000989 12 10% 5% 0% -5% -10% -15% -20% -25% 04-12-29 05-3-29 05-6-29 05-9-29 «2006»
...1...1...1...2...2...3...4...4...5...7 :...8 :...12 :...17 : I131...24 :...29 1
1...2 2 2003 2005H...2 3...3 4...5 1...3 2: ( )...4 2
1993 1993 60 1986 1 1 1993 1 1 7 6 2 1984 1999 5 1 12 8 6 2002 9 15 2003 2 12 SFDA 2002 9 15 2002 9 15 5 4 3 1
1 SFDA 2003 2005 SFDA 236 2 2003 2005H 2003 2004 2005H 76 11 91 14 61 9 228 17 3 3 4 1 5 1000 FDA 2
1 5000 5 6 5000-10000 802 1 2 I 5 1 2 II 3 III 318 1 1 2 138 12 15 1975 1987 2000 3 $ 1 108.62 2 51.97 3 /45.04 4 44.63 5 44.20 6 38.83 7 35.89 8 33.61 9 33.47 10 33.27 0 3
1 0 1 2: ( ) 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 85% 60% 50% 45% 40% 25% : 4
4 5 45% SFDA 42 2006 EPS 0.164 0.123 0.082 2006 2007 2002 II 7000 9 5
3 2008 0.871 6968 : 3 35% 5 0.08 :, 1.5 GMP 2006 2006 1/4 2007 1/2 2008 2006 2007 2008 3750 7500 15000 : Natrecor Natrecor 6.67% 2006 1/3 2007 1/2 2008 1480 20% 2006 2007 2008 1776 2664 5328 EPS 0.14 0.22 0.44 2005 4 Natrecor 1.3 3000 300 500,, 6
,, 2.5 2006 ( ) 7
: 0.021% 50 68% 70 2 3 70 600 5000 1000 2002 90% 2002 1 2% 98% 8
1989 1997 12 1999 11 2835 2001 GMP 2005 5 5850 45% 2003 9 SFDA 2004 1 21 SFDA 42 2005 7 SFDA 2005 ( ) 2 3 9
4 /Kg 140000 130000 120000 100000 80000 60000 40000 20000 0 60000 300 89100505 01133550 ZL99238345.5 1999 1 10
2 SFDA 42 5 5000 2006 1000 5 / 80% 30% 45% 7670 0.082 1 100% 75% 50% 5 / 80% 30% 2800 2100 1400 1260 945 630 0.164 0.123 0.082 0.3 2006 2007 11
12 : COX-1 COX-2 COX-1 COX-2 NSAIDs COX NSAIDs 3 COX 2 NSAIDs 1 NSAIDs COX COX 1 COX 2 COX 1 COX 2 COX 2 COX 1 COX 2 COX 1 COX 1 A2(TXA2) COX 2 COX 2 COX 1 NSAIDs COX 2 1999 2 2002 95 30 32% 1999 5 8000
80 2003 25 COX-2 2000 VIGOR( ) 3 2 0.4% 0.1% 2004 8 25 David graham 20 FDA 140 NSAIDs 40405 26748 (>25mg) 3.15 (<25mg) 2004 10 2004 12 FDA 2005 8 19 2.53 4200 2002 White CLASS ( ) NSAIDs 0.2% 0.1% NCI APC 400 800 33 2.5 3.4 NCI Solomen COX-2 NSAIDs NSAIDs 60% 40% 60% NSAIDs 1 30 31 90 40% 38% NSAIDs 13
Mamdani 2004 Lancet NSAIDs NSAIDs NSAIDs FDA 140 NSAIDs 25mg/d NSAIDs 3.15 2004 3 ACC NSAIDs 2.45 2005 4 FDA 2004 10 14 COX-2 2005 2 FDA /COX-2 COX-2 3 COX-2 COX-2 (EMA) COX-2 COX-2 1999 COX-2 COX-2 14
2001 300 40 2002 II 7000 9 7000 2002 COX-2 3 1 2 3 2003 2.1 5% 2008 2.68 70% 65% 2008 0.871 2.68 *65%*50% 80% 6968 1: ( ) 15
100% 80% 60% 40% 20% 85% 60% 50% 45% 40% 25% 0% 16
: 1 Purkinje : 17
18 1: : Vaughan Willims, β 40
2: Ap ( ) a (ajmaline) (pirmenol) (aprindine) b (mexiletine) c = (encainide) (tocainide) (flecainide) (lorcainide) (propafenone) (ethmozin) (β ) = β ( = (sotabl) ) (bepridil) : 2000 500 28 78% 20% 2001 527.55 2.3 0.436% 2000 2025 65 7% 12% 20% 7% 2004 270 19
AMI0dAr0ne 1962 Labaz 1967 1995 2000 80% PropAFenone rythm0l c 1970 1977 1989 FDA 2000 rythm0l 1.77 2002 120 0.57 2000 Verapamil 10% Sotalol 1965 β S0tAc0r 1974 BetA card0ne 40 β1 β2 90 100% 30-60% 2002 71 1.11 β 8% 20
1994 1995 1999 2001 2002 863 L Na 2 21
2003 190 8 10% 2003 17 2001 2.3 2003 1% 2003 190 1.9 2002 7% 8-10% 2004 270 2003 1% 2004 2.7 2003 35% 2004 2004 1.13 2004 3.23 3 2004 5 48.16% 59.17% 22
3: ( ( 60% 20%) ( 1.2 13600 2720 0.32 ) ( ) 0.6 6780 1356 0.16 ) 0.3 3390 678 0.08 ( ) 0.1 1130 226 0.03 : ) 3 35% 5 0.32 0.16 0.08 0.03 2004 EPS1.03 31% 16% 7.7% 2.9% 23
24 : I131 5 20.6% 80% 1 25 75 3807 35.5-62.5 B CT 10 : FDA
2 16 (IFO) 57.02 * 5- (5-Fu) 55.07 * (VM26) 53.31 * (TAL) 52.18 * (DDP) 51.27 * (CTX) 51.26 * (BLM) 47.9 (PAC) 47.15 (Ara-C) 47.07 (MeCCNU) 46.74 (MMC) 46.26 (ADM) 45.74 (CBD) 41.82 (MTX) 41.53 (VCR) 39.23 (VP16) 25.45 (%) 50% 5- Eli Lilly gemcitabine 1996 0.64 2002 3.90 2 8:1 30-60 25
30 30 11 45 20 20 70 8.5 56 IARC 12 2000 30.6 2005 34.5 2000 28 2005 30 (21.76%) (17.83%) (15.19%) 160 170 29.4 20/10 13 26 3 1990 1992 (1/10 ) 108.26 112.57 106.91 134.91 80.04 25.16 19.44 27.16 32.84 17.02 20.37 19.50 20.67 29.01 11.21 17.54 27.50 14.05 24.03 10.66 17.38 9.62 20.10 22.14 12.34 5.30 6.98 4.72 5.76 4.82 3.64 3.66 3.63 3.96 3.30 1.89 1.58 2.00-3.89 1.74 1.93 1.67 2.34 1.10 1.72 2.56 1.42-3.53 1.01 1.53 0.83 1.46 0.53 1990 1992 11 70 I131 50 I131 26
2001 3650 [131I] 2004 1675 4000 PCT 3 12 4 16% 80% 27% 86% 42% 32 31%, 2, 2, :, 1 1004 300 300 500 500 1000 1000 1500 1500 16.5% 36.6% 25.4% 14.4% 7.1% 65 4.6% 53.8% 30% 11% 5% 27
1.5 1.5 30 *5%*1 / 5 1.5 GMP 2006 2006 1/4 2007 1/2 2008 2006 2007 2008 3750 7500 15000, 20% 30% 2006 2007 2008 1125 2250 4500 12798 0.08 0.17 0.35 2008 EPS 0.35 10 3 9 12 30 50% 28
29 : CHF ESC 490 40 70 1.5% 2.0% 65 6% 10% 8 6 2000 2001 0.9% 35 74 400 5 50 20% 40% Andreas Bundkirchen 1 2% 400 80 150 10.9% 2005 60 CHF 1 5 2005 ESC BNP 1988 BNP BNP
60% BNP BNP BNP 2005 ESC RAAS Natrecor 2001 2002 3 8 7180 2005 4 22 SFDA Natrecor 5 Natrecor 4 6.67% SFDA 2005 453 45% 20% 40 Natrecor 2.67 Natrecor 4 Natrecor 2006 1/3 2007 1/2 2008 8900 1.34 2.67 1480 6 9 18 20% 2006 2007 2008 1776 2664 5328 EPS 0.14 0.22 0.44 2006 1 14 2005 3800 EPS 0.31 20% Natrecor Natrecor 30
2005 4 Natrecor FDA 30 7 5.3% 4.3% Natrecor 4 ESC 2005 31
8 3 130 5 430015 200002 8627 65799881 8621 63296362 8627 65799501 8621 63294763 12 /, 12 /, 10% 5% 10% -5% 5% -5% http:// www.cjsc.com.cn